Annie Chan, MD
Ophthalmology · Santa Clara
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 4
- 1 carrier
- Offices
- 2
Offices
2 locations · Permanente Medical Group Inc · 10,928 clinicians in this group
Plans that list them
4 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Chan’s office at (408) 851-1000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Kaiser Permanente Dual Complete North P2 (HMO D-SNP) | Kaiser Permanente | Listed | Sep 1, 2026 |
| Kaiser Permanente Dual Complete North P23 (HMO D-SNP) | Kaiser Permanente | Listed | Sep 1, 2026 |
| Kaiser Permanente Sr Adv Basic Santa Clara (HMO) | Kaiser Permanente | Listed | Sep 1, 2026 |
| Kaiser Permanente Sr Adv Enhanced Santa Clara (HMO) | Kaiser Permanente | Listed | Sep 1, 2026 |
California Medical Board record
Licence A96575 · Current
Licensed to practise in California · since 2006 · expires 2028-05-31 · Tufts University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Medicaid work
$123,464 in 2024
Medicaid paid $123,464 for 618 billed services this clinician did in 2024, up to 30 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Intravitreal injection of a pharmacologic agent (separate procedure) | 166 | $52,698 |
| Aflibercept injection | 12 | $31,460 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 230 | $27,146 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 210 | $12,159 |
| 2024 | 618 | 4 | 30 | $123,464 |
| 2023 | 678 | 4 | 27 | $8,955 |
| 2022 | 315 | 3 | 18 | $1,338 |
| 2021 | 152 | 3 | 15 | $450 |
| 2020 | 44 | 2 | 15 | $69 |
| 2019 | 29 | 2 | 15 | $0 |
See the largest Medicaid services in earlier years
2023
| Intravitreal injection of a pharmacologic agent (separate procedure) | 217 | $4,670 |
| Aflibercept injection | 25 | $3,739 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 222 | $329 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 214 | $217 |
2022
| Intravitreal injection of a pharmacologic agent (separate procedure) | 75 | $618 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 122 | $487 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 118 | $233 |
2021
| Intravitreal injection of a pharmacologic agent (separate procedure) | 57 | $376 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 55 | $74 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 40 | $0 |
2020
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 30 | $37 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 14 | $32 |
2019
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 16 | $0 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 13 | $0 |
Drugs they prescribed that Part D paid
$6,607
Pharmacies billed $6,607 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 87) in 2024. At or below the middle of the specialty; the typical ophthalmology clinician is at 0%.
67 generic and 20 brand-name prescriptions · $6,607 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Prednisolone Acetate | 15 | $1,054 | $70 |
| Latanoprost | 13 | $150 | $12 |
| Diclofenac | 11 | $138 | $13 |
Year by year
| 2024 | 87 | 33 | 0% (0) | 23% | $6,607 |
| 2023 | 91 | 35 | 0% (0) | 32% | $11,558 |
| 2022 | 98 | 34 | 0% (0) | 34% | $6,822 |
| 2021 | 122 | 38 | 0% (0) | 25% | $8,035 |
| 2020 | 102 | 29 | 0% (0) | 11% | $5,413 |
| 2019 | 98 | 42 | 0% (0) | None | $12,437 |
| 2018 | 76 | 33 | None | 32% | $9,837 |
| 2017 | 84 | 37 | 0% (0) | 27% | $10,654 |
| 2016 | 78 | 33 | 0% (0) | 24% | $10,070 |
| 2015 | 70 | 34 | 0% (0) | 31% | $12,887 |
| 2014 | 87 | 52 | None | 46% | $11,299 |
| 2013 | 98 | 37 | None | 47% | $16,200 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 3 drugs
| Difluprednate | 12 | $3,406 | $284 |
| Prednisolone Acetate | 17 | $1,175 | $69 |
| Dorzolamide-Timolol | 13 | $316 | $24 |
2022: 4 drugs
| Brimonidine | 18 | $1,595 | $89 |
| Prednisolone Acetate | 12 | $905 | $75 |
| Dorzolamide-Timolol | 18 | $357 | $20 |
| Latanoprost | 12 | $149 | $12 |
2021: 3 drugs
| Dorzolamide-Timolol | 16 | $322 | $20 |
| Latanoprost | 25 | $302 | $12 |
| Brimonidine | 20 | $234 | $12 |
2020: 3 drugs
| Dorzolamide-Timolol | 15 | $339 | $23 |
| Latanoprost | 20 | $304 | $15 |
| Brimonidine | 22 | $248 | $11 |
2019: 2 drugs
| Nevanac | 13 | $8,211 | $632 |
| Latanoprost | 23 | $313 | $14 |
2018: 2 drugs
| Nevanac | 12 | $5,825 | $485 |
| Latanoprost | 15 | $250 | $17 |
2017: 3 drugs
| Nevanac | 12 | $3,734 | $311 |
| Latanoprost | 11 | $184 | $17 |
| Brimonidine | 11 | $136 | $12 |
2016: 2 drugs
| Dorzolamide | 15 | $323 | $22 |
| Brimonidine | 12 | $233 | $19 |
2015: 3 drugs
| Nevanac | 11 | $9,356 | $851 |
| Brimonidine | 16 | $290 | $18 |
| Dorzolamide-Timolol | 17 | $286 | $17 |
2013: 2 drugs
| Dorzolamide-Timolol | 19 | $711 | $37 |
| Brimonidine | 12 | $204 | $17 |
Money from drug and device companies
$94 in 2025
| 2025 | 1 | 1 | None | $94 |
| 2024 | 1 | 1 | None | $104 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Astellas Pharma US | Izervay | $94 | 1 payment
|
See the published payment
| Astellas Pharma US | Meals · 2025-08-02 | Izervay | $94 |
See earlier years (2024)
2024: $104
| EyePoint Pharmaceuticals US | Eyp-1901 | $104 | 1 payment
|
Professional record
- NPI
- 1346420221
- Licence
- CA A96575California A96575: Current · expires 2028-05-31
- Trained
- Tufts University School of Medicine, 2005
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207W00000X (207W00000X)
- Mailing address
- Po Box 60000, File 74010, San Francisco, CA, 94160
- NPI first listed
- 2007-11-08
- NPI last updated
- 2021-12-22
This is when the NPI record was last certified, not a medical board exam.
This office lists an electronic records connection.